Skip to content
Medical Health Aged Care

GPs celebrated on World Family Doctor Day

Royal Australian College of GPs 2 mins read

Australia's GPs are being celebrated for their work helping people live healthier and contributing to communities across the country, in the lead up to World Family Doctor Day on Sunday 19 May. 

The Royal Australian College of GPs (RACGP) President Dr Nicole Higgins said the expertise and contributions of Australia’s specialist general practitioners is often unrecognised and underappreciated. 

“Many people don’t realise GPs are specialists. We do the same eight years medical training as any other medical specialist, plus at least three years training in a practice to specialise as a GP,” she said. 

The role GPs play in our health system is unique. GPs are the only specialists who provides ‘whole person care’, from the start of life right up until the end 

Research shows the value of the GP-patient relationship, and how it results in better health. People who have a regular GP have less hospital admissions and live longer, healthier lives 

“GPs are the most visited health professional in our country – more than 22 million Australians received 179 million services from GPs in 2022. 

General practice is also the most cost-effective form of care – it costs taxpayers over $600 when someone goes to hospital, before they’re even admitted, whereas it’s only $80 for 40 minutes with a GP. 

“GPs are needed now more than ever. Our demographics show that we have an ageing population, and nearly half of all Australians are living with chronic illness, including mental health issues.  

This means more people require complex, ongoing care in the community from a GP, who knows them and works together with other specialists, allied health, nurses, and pharmacists to ensure they gets the best care, and – just as importantly - the right care, at the right time. 

“This World Family Doctor Day, I want to thank Australia’s GPs for their contributions in helping Australians live healthier and longer and keeping the engine of our world class health system running.” 

~ ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992media@racgp.org.au

Follow us on Twitter: @RACGP and Facebook.

More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.